Fat Loss Support
Body Recomposition — Retatrutide & CJC-1295 DAC
Advanced educational protocol discussing GLP-1/GIP/glucagon triple agonism combined with long-acting GHRH stimulation for body recomposition research
• This protocol is provided for educational and informational purposes only. It does not constitute medical advice, a diagnosis, a treatment plan, or a prescription.
• All dose ranges, frequencies, durations, and compound selections must be determined by a licensed healthcare professional based on your individual medical history, lab results, and clinical assessment.
• Lab monitoring may be required depending on the compound(s), individual health status, and duration of use. Discuss appropriate monitoring protocols with your clinician.
• Do not use any peptide compound if you are pregnant, breastfeeding, a minor, or have uncontrolled medical conditions without explicit direction from your physician.
High Risk — Specialist Supervision Required
Significant safety considerations; not suitable for unsupervised use
Overview
This advanced educational protocol outlines research discussion points for combining a potent triple GI-axis agonist (Retatrutide) with a long-acting GHRH analogue (CJC-1295 DAC). The theoretical research basis centers on simultaneous reduction in adipose tissue via GLP-1/GIP/glucagon receptor engagement alongside GH-axis-mediated lean mass and metabolic support. This combination represents an active area of clinical research. All practical application requires licensed physician oversight with comprehensive metabolic and hormonal monitoring.
Mechanism Summary
Retatrutide engages three distinct receptors: GLP-1R (satiety signaling, glucose-dependent insulin secretion), GIPR (energy homeostasis, fat storage modulation), and glucagon receptor (hepatic glucose output, lipolysis stimulation). The triple agonism produces synergistic metabolic effects exceeding those of single or dual agonists in trial data. CJC-1295 DAC is a modified GHRH analogue with a DAC (Drug Affinity Complex) linker that binds circulating albumin, extending the elimination half-life to approximately 6–8 days. This produces sustained pulsatile GH release and downstream IGF-1 elevation, which may support lean mass preservation during aggressive caloric restriction phases. The theoretical synergy — aggressive lipolysis + preserved anabolism — is the focus of this research discussion.
Intended Goal
Prepare for a clinician consultation on combining a triple GI-axis agonist with a long-acting GH secretagogue for simultaneous fat reduction and lean mass considerations
Retatrutide (LY3437943)
CalculateResearch category: GLP-1 / GIP / glucagon triple agonist
Investigational triple receptor agonist (GLP-1R, GIPR, GcgR) studied in Phase II/III trials for obesity and metabolic disease. Significant weight reduction observed in clinical trials. Not FDA-approved as of 2025. Catalog reference only.
CJC-1295 DAC
CalculateResearch category: Long-acting GHRH analogue / GH secretagogue
Drug Affinity Complex (DAC) modification extends half-life to ~6–8 days via albumin binding. Studied for sustained GH and IGF-1 elevation. Catalog reference only.
Who may be a candidate
- ✓Adults with clinician-confirmed obesity or significant excess adiposity being treated in a clinical context
- ✓Individuals already experienced with GLP-1 class compounds under medical supervision
- ✓Those with comprehensive baseline hormonal and metabolic labs completed
- ✓Patients with a licensed physician directing the overall program
Exclusions
- ✕Not appropriate for individuals new to peptide research — see Foundation Overview protocol first
- ✕Not appropriate without active clinician supervision
- ✕Not a substitute for established anti-obesity pharmacotherapy
- ✕Not intended for lean individuals seeking cosmetic-only recomposition
Am I a candidate for a GLP-1/GIP/glucagon triple agonist like Retatrutide given my metabolic profile?
What does my current IGF-1 level indicate, and is CJC-1295 DAC appropriate?
How would you monitor for IGF-1 overshoot given the long half-life of CJC-1295 DAC?
What stopping criteria would you use for each compound individually?
How does Retatrutide's impact on gastric emptying affect the absorption of my other medications?
Are there any active clinical trials for Retatrutide I might qualify for?
Print or copy these questions using the "Copy Summary" button to bring to your appointment.
Legal & Compliance Notice
Retatrutide is investigational and not approved for general use as of 2025. CJC-1295 DAC regulatory status varies by country. Verify current legal status with a licensed clinician before any practical consideration.
The legal and regulatory status of research compounds varies by country and jurisdiction. It is the user's responsibility to understand applicable local laws before engaging with any compound.
This application does not provide personalized dosing recommendations. Users who require medical guidance should consult a qualified clinician.
Last reviewed: 2025-03-01 · Status: reviewed
Talk to a Licensed Clinician
The information in this protocol is for educational reference only. Before considering any compound, schedule a consultation with a qualified healthcare professional who can review your personal health history, order appropriate labs, and provide personalized guidance.